600055.SH
万东医疗
SSE · Healthcare · Medical - Devices · CN
CNY 10.81
−3.05%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.3B | 1.5B | 1.2B | 1.1B |
| Cost of Revenue | 1.1B | 989.2M | 967.1M | 716.4M | 626.6M |
| Gross Profit | 317.8M | 357.8M | 557.2M | 520.3M | 494.6M |
| Operating Expenses | |||||
| R&D Expense | 259.9M | 263.2M | 165.2M | 157.6M | 137.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 126.1M | 129.3M | 69.6M | 80.8M | 67.7M |
| Selling & Marketing Expense | 272.3M | 277.1M | 219.4M | 219.5M | 174.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 645.4M | 644.7M | 394.3M | 389.7M | 325.0M |
| Cost and Expenses | 1.7B | 1.6B | 1.4B | 1.1B | 951.6M |
| Operating Income (EBIT) | (350.8M) | (297.2M) | 163.3M | 213.3M | 192.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (355.0M) | (300.5M) | 166.9M | 213.3M | 192.4M |
| Income Tax Expense | (76.7M) | (72.7M) | 8.2M | 22.5M | 20.4M |
| Bottom Line | |||||
| Net Income | (278.8M) | (227.9M) | 157.4M | 188.5M | 175.4M |
| Earnings from Cont. Ops | (278.3M) | (227.8M) | 158.6M | 190.8M | 172.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (278.8M) | (227.9M) | 157.4M | 188.5M | 175.4M |
| Per Share | |||||
| Basic EPS | (CN¥0.39) | (CN¥0.32) | CN¥0.22 | CN¥0.27 | CN¥0.27 |
| Diluted EPS | (CN¥0.39) | (CN¥0.32) | CN¥0.22 | CN¥0.27 | CN¥0.27 |
| Revenue Per Share | CN¥1.99 | CN¥1.89 | CN¥2.13 | CN¥1.77 | CN¥1.73 |
| Shares | |||||
| Basic Shares Outstanding | 692.8M | 712.1M | 715.2M | 698.3M | 649.5M |
| Diluted Shares Outstanding | 692.8M | 712.1M | 715.2M | 698.3M | 649.5M |
| Profitability Metrics | |||||
| EBITDA | — | (253.1M) | 201.6M | 250.3M | 228.1M |
| D&A | — | 44.1M | 38.3M | 37.0M | 35.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026